

## Strong pricing power with improving volumes

We maintain our positive outlook on Marico (MRCO IN) as it demonstrated strong potential for double-digit sales growth in the medium term, fueled by price growth, focus on direct reach and robust performance in its Foods and Premium Personal care segments. Furthermore, there is an upside risk in margin in the long term as new business scales up. We upgrade to Buy from Accumulate with a higher TP of INR 752 from INR 730 on 50x (unchanged) on as we roll-forward to Dec '26E P/E.

**Volume improved sequentially, as expected:** Q2 net sales increased by 7.6% YoY to INR 26.6bn, meeting expectations, driven by an 8% rise in the domestic business, with volume growth improving to 5% from 4% in Q1. The *Parachute* segment grew 4% in volume, even after a minor volume impact from volume reduction in a key price point. *Saffola* edible oil saw flat volume growth and a 2% value increase as the pricing cycle turned slightly favorable after eight quarters. Value-added hair oil (VAHO) dropped 8% YoY due to market sluggishness and competition, particularly in the lower segment. However, Foods grew 28% YoY, supported by mid-teen growth in *Saffola* oats, achieving a milestone with >INR 10bn in annual revenue run-rate (ARR). The management anticipates stronger domestic revenue growth in H2, with support from pricing adjustments (including additional 4% price hike in *Parachute* and a 15% price hike in edible oils due to higher import duties) and gradual volume gains. The international business delivered 13% growth in constant-currency. MRCO aims to maintain this double-digit growth in the medium term.

**Project SETU progressing as planned; digital-first portfolio scaling in-line:** Project SETU, aimed at expanding direct outlet reach, has now extended to four more states, bringing its reach to a total of 10 states, with promising initial results. Additionally, the new digital-first portfolio has performed ahead of expectations, surpassing ARR of INR 5.25bn in Q2. In the domestic market, the combined revenue share of Foods and Premium Personal Care, including Digital-first brands, rose to ~21% in H1, with a target to grow to ~25%+ by FY27.

**Levers in place to drive margin expansion in the long term**: EBITDA margin contracted 50bps YoY to 19.6%, in-line with our expectations. For FY25, although the management previously indicated a goal to sustain EBITDA margin at FY24 level, the recent increase in input costs may affect margin by 40-50bps YoY. Nevertheless, long-term outlook is positive, with anticipated margin expansion driven by improvements in Food segments and digital-first brands (as the business continues to scale), favorable product mix and focus on premiumization.

**Upgrade to Buy with a higher TP of INR 752**: We largely maintain our estimates for FY25, FY26 and FY27 and upgrade MRCO to **Buy** from Accumulate as stock has corrected by 8% in the past three months. We arrive at a higher TP of INR 752 from INR 730 on 50x (unchanged) on as we roll-forward to Dec '26E P/E.

#### **Key Financials**

YE March	FY23	FY24	FY25E	FY26E	FY27E
Revenue (INR mn)	97,640	96,530	105,638	115,861	128,290
YoY (%)	2.6	(1.1)	9.4	9.7	10.7
EBITDA (INR mn)	18,100	20,260	21,861	24,163	26,883
EBITDA margin (%)	18.5	21.0	20.7	20.9	21.0
Adj PAT (INR mn)	13,020	14,810	15,973	17,782	19,925
YoY (%)	6.3	13.7	7.9	11.3	12.1
Fully DEPS (INR)	10.1	11.5	12.4	13.8	15.4
RoE (%)	36.4	38.8	38.2	36.1	34.7
RoCE (%)	44.0	44.8	44.3	42.6	41.5
P/E (x)	62.3	54.8	50.8	45.6	40.7
EV/EBITDA (x)	44.1	39.5	36.2	32.4	28.8

Note: Pricing as on 29 October 2024; Source: Company, Elara Securities Estimate

#### 30 October 2024


Rating: Buy
Target Price: INR 752
Upside: 20%
CMP: INR 629
As on 29 October 2024

#### Kev dat

Key data	
Bloomberg	MRCO IN
Reuters Code	MRCO.NS
Shares outstanding (mn)	1295
Market cap (INR bn/USD mn)	815/9688
Enterprise Value (INR bn/USD mn)	811/9648
Avg daily volume 3M (INR mn/USD mn)	1916/23
52 week high/low	720/486
Free float (%)	41

Note: as on 29 October 2024; Source: Bloomberg

#### Price chart



Source: Bloomberg

Shareholding (%)	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25
Promoter	59.4	59.4	59.3	59.2
% Pledged	0.1	0.1	0.1	0.1
FII	25.7	25.5	24.6	24.9
DII	10.0	10.2	11.4	11.3
Others	4.9	4.9	4.7	4.6
Source: BSE				

Price performance (%)	3M	6M	12M
Nifty	(1.5)	8.1	28.5
Marico	(7.9)	22.0	17.0
NSE Mid-cap	(3.6)	10.7	45.3
NSE Small-cap	(4.4)	6.9	44.0

#### Amit Purohit

Building Materials, FMCG, Paints +91 22 6164 8594 amit.purohit@elaracapital.com

Associates Rohit Harlikar Vidhi Puj



Elara Securities (India) Private Limited

# Financials (YE March)

Income statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Net Revenue	97,640	96,530	105,638	115,861	128,290
EBITDA	18,100	20,260	21,861	24,163	26,883
Less: Depreciation & Amortisation	1,550	1,580	1,660	1,741	1,821
EBIT	16,550	18,680	20,200	22,422	25,063
Less: Interest Expense	560	730	720	720	720
Add: Other Income	1,440	1,420	1,519	1,629	1,753
PBT	17,430	19,370	20,999	23,332	26,095
Less Taxes	4,210	4,350	4,716	5,240	5,860
Reported PAT	13,220	15,020	16,283	18,092	20,235
Minority Interest	200	210	310	310	310
Reported PAT after Minority Interest	13,020	14,810	15,973	17,782	19,925
Adjusted PAT	13,020	14,810	15,973	17,782	19,925
Balance Sheet (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	1,290	1,290	1,290	1,290	1,290
Reserves	36,700	37,030	44,013	51,818	60,554
Minority Interests	1,570	3,370	3,370	3,370	3,370
Borrowings	4,750	3,830	3,830	3,830	3,830
Deferred Tax (Net)	320	2,110	2,110	2,110	2,110
Total Liabilities	44,630		,		
Gross Block		<b>47,630</b> 37,180	<b>54,613</b> 38,380	62,418	<b>71,154</b>
	31,150	,	,	39,580	40,780
Less: Accumulated depreciation	8,690	9,940	11,612	13,353	15,174
Net Block	22,460	27,240	26,768	26,227	25,606
Capital work in progress	670	440	320	320	320
Investments	10,960	6,020	6,020	6,020	6,020
Cash	7,560	9,430	17,297	25,213	33,929
Net working capital	2,980	4,500	4,208	4,638	5,278
Total Assets	44,630	47,630	54,613	62,418	71,154
Cash flow statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Operating cash flow	16,250	14,870	17,926	19,093	21,105
Less: Capex	6,690	6,130	1,068	1,200	1,200
Free cash flow to firm	9,560	8,740	16,858	17,893	19,905
Investing cash flow	(9,370)	(1,190)	(1,068)	(1,200)	(1,200)
Financing cash flow	(5,110)	(11,810)	(8,991)	(9,977)	(11,188)
Net change in cash	1,770	1,870	7,867	7,916	8,717
Ratio Analysis	FY23	FY24	FY25E	FY26E	FY27E
Income statement Ratios (%)					
Revenue growth	2.6	(1.1)	9.4	9.7	10.7
EBITDA growth	7.7	11.9	7.9	10.5	11.3
PAT growth	6.3	13.7	7.9	11.3	12.1
EBITDA margin	18.5	21.0	20.7	20.9	21.0
Net margin	13.3	15.3	15.1	15.3	15.5
Return and liquidity ratios					
Net debt/Equity (x)	(0.2)	(0.2)	(0.4)	(0.5)	(0.5)
ROE (%)	36.4	38.8	38.2	36.1	34.7
ROCE(%)	44.0	44.8	44.3	42.6	41.5
Per share data and Valuation ratios					
Diluted EPS (INR)	10.1	11.5	12.4	13.8	15.4
EPS growth (%)	6.3	13.7	7.9	11.3	12.1
DPS (INR)	4.5	9.5	6.0	6.6	7.4
P/E ratio (x)	62.3	54.8	50.8	45.6	40.7
EV/EBITDA (x)	44.1	39.5	36.2	32.4	28.8
			7.5		
EV/Sales (X)	8.2	8.3		6.8	6.0
Price/Book(x)	21.4	21.2	17.9	15.3	13.1
FCFF yield (%)	1.1	1.0	2.0	2.1	2.3
Dividend yield (%)	0.7	1.5	0.9	1.1	1.2

We expect a revenue CAGR of 10% in FY24-27E

Margins to remain flat at 21% in FY24-27E

Note: Pricing as on 29 October 2024; Source: Company, Elara Securities Estimate

Sales growth aided by sequential volume uptick in domestic business and pricing cycle turning favorable in edible oil

EBITDA margin was in-line with our expectation; margin outlook is slightly weak due to rise in input prices

#### **Quarterly financials**

Y/E March (INR mn)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Q2FY25E	Variance (%)
Net sales	26,640	24,760	7.6	26,430	0.8	26,640	(0.0)
Operating expenses	21,420	19,790	8.2	20,170	6.2	21,382	0.2
% of sales	80.4	79.9		76.3		80.3	
EBITDA	5,220	4,970	5.0	6,260	(16.6)	5,258	(0.7)
EBITDA margins (%)	19.6	20.1		23.7		19.7	
Other income	820	380	115.8	370	121.6	300	173.3
Interest	110	200		170		170	
Depreciation	410	390		410	-	420	(2.4)
PBT	5,520	4,760	16.0	6,050	(8.8)	4,968	11.1
Tax	1,190	1,160	2.6	1,310	(9.2)	1,150	3.5
Effective tax rate (%)	21.6	24.4		21.7		23.1	
Minority interest	100	70.0		100.0		80.0	
Reported PAT	4,230	3,530	19.8	4,640	(8.8)	3,738	13.2
Adjusted PAT	4,230	3,530	19.8	4,640	(8.8)	3,738	13.2
NPM (%)	15.9	14.3		17.6		14.0	


Source: Company, Elara Securities Estimate

## Exhibit 1: Key ratios

YE March (%)	Q2FY25	Q2FY24	YoY bps chg	Q1FY25	QoQ bps chg	Q2FY25E	bps variance
Raw material cost	49.2	49.5	(30)	47.7	146	49.6	(38)
Staff costs	8.0	7.6	44	7.7	31	8.0	0
Advertising expenses	10.9	10.8	6	9.1	181	10.2	68
Other expenses	12.3	12.0	28	11.8	51	12.5	(15)
Effective tax rate	21.6	24.4	(281)	21.7	(9)	23.1	(159)
Gross margin	50.8	50.5	30	52.3	(146)	50.4	38
EBITDA margin	19.6	20.1	(48)	23.7	(409)	19.7	(14)
NPM	15.9	14.3	162	17.6	(168)	14.0	185


Source: Company, Elara Securities Estimate

#### Exhibit 2: Volume growth improved sequentially



Source: Company, Elara Securities Research

## Exhibit 3: Margin slightly dipped YoY due to higher operating expenses



Source: Company, Elara Securities Research



## Exhibit 4: Segment-wise performance – Subdued growth in Saffola Edible Oil and VAHO

Category	Q2FY25 value growth (%)	Q2FY25 volume growth (%)	Market share (%)	Comments
Parachute				<ul> <li>Parachute Rigid registered 4% volume growth and 6% value growth. Decrease in volume in one of the key price points impacted volume growth by 1%.</li> </ul>
coconut oil (PCNO)	10	4	54 (volume share)	<ul> <li>Volume offtakes grew in high single-digit, resulting in ~120bps gain in market share on MAT basis.</li> </ul>
				<ul> <li>MRCO implemented another round of price hikes of ~4% at the end of Q2.</li> </ul>
				<ul> <li>Saffola Edible Oils registered flat volume growth, while revenues grew 2% YoY after the pricing cycle for the brand turned slightly favorable.</li> </ul>
				<ul> <li>The brand implemented a price increase of ~15% for edible oil in response to the sharp hike in import duties on vegetable oils recently.</li> </ul>
Saffola	Edible oil: 2	Edible oil: flat volume		<ul> <li>Foods ARR crossed INR 10bn.</li> </ul>
	Foods: 28	growth	Oats: 41 (value share)	<ul> <li>Saffola Oats delivered mid-teen growth, while newer franchises also fared healthily.</li> </ul>
				<ul> <li>Saffola Masala Millets was launched in Q2.</li> </ul>
				<ul> <li>True Elements and the plant-based nutrition portfolio of Plix maintained accelerated growth momentum.</li> </ul>
				<ul> <li>Value-added hair oils declined 8% in value terms amid persistent sluggishness and competitive headwinds in the bottom of the pyramid segment.</li> </ul>
Value added hair	(8)	NA	28 (value share)	<ul> <li>The franchise gained ~110bps in value market share in Q2, as mid and premium segments of the franchise fared better.</li> </ul>
oils (VAHO)				<ul> <li>The growth trajectory of the franchise has bottomed out and MRCO expects gradually improving trends ahead on the back of visible ATL investments and brand activations leading into the festive season.</li> </ul>
				<ul> <li>The Digital-first brands crossed INR 5.25bn in ARR in Q2.</li> </ul>
Premium			Post wash Leave-on Serums – 48% (volume share)	<ul> <li>Beardo continued to scale ahead of expectations and is on course to deliver double-digit EBITDA margin this year.</li> </ul>
personal care	NA	NA	hair gels/waxes/creams 52% (volume share)	<ul> <li>Beardo continued to scale well and is on course to deliver double-digit EBITDA margin this year.</li> </ul>
				<ul> <li>Just Herbs and personal care portfolio of Plix continued to gain traction.</li> </ul>


Source: Company, Elara Securities Research

## Exhibit 5: International business – Strong performance in MENA and South Africa regions

Geography	Q2FY25 constant- currency (CC) growth (%)	Comments
Bangladesh	8	<ul> <li>The business stayed resilient amidst challenges in the operating environment, which progressively subsided in the latter half of Q2.</li> </ul>
South East Asia	7	Growth led by recovery in home and personal care (HPC) demand in Vietnam.
Middle East and North Africa (MENA)	43	<ul> <li>Strong momentum in the MENA region was led by robust growth in Egypt and the Gulf region.</li> </ul>
South Africa	20	Strong growth in South Africa with both the Hair Care and Health Care franchises faring well.

Source: Company, Elara Securities Research

## Exhibit 6: Trading above its five-year average P/E of 45x



Source: Bloomberg, Company, Elara Securities Estimate

## Exhibit 7: Valuation overview

12.0
13.8
15.4
50
15
752


Source: Elara Securities Estimate

## Exhibit 8: Change in estimates

(INR mn)	Earlier			Revised			% Change		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	104,889	115,433	127,859	105,638	115,861	128,290	0.7	0.4	0.3
EBITDA	21,944	24,182	26,825	21,861	24,163	26,883	(0.4)	(0.1)	0.2
EBITDA margin (%)	20.9	20.9	21.0	20.7	20.9	21.0	(23)	(9)	(3)
PAT	16,038	17,797	19,880	15,973	17,782	19,925	(0.4)	(0.1)	0.2
EPS (INR)	12.4	13.8	15.4	12.4	13.8	15.4	(0.4)	(0.1)	0.2
TP (INR)			730			752			2.9
Rating			Accumulate			Buy			

Source: Elara Securities Estimate

## Coverage History



	Date	Rating	Target Price	<b>Closing Price</b>
22	3-Feb-2023	Accumulate	INR 560	INR 494
23	5-May-2023	Buy	INR 590	INR 494
24	2-Jun-2023	Accumulate	INR 603	INR 549
25	28-Jul-2023	Accumulate	INR 623	INR 574
26	29-Jan-2024	Accumulate	INR 580	INR 517
27	6-May-2024	Accumulate	INR 600	INR 530
28	5-Aug-2024	Accumulate	INR 730	INR 672
29	29-Oct-2024	Buy	INR 752	INR 629

## Guide to Research Rating

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%



## **Disclosures & Confidentiality for non U.S. Investors**

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient of in understanding / evaluating the Proposal. Nothing in this document factor buy or sell to solicitation to buy or solicit securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client afficients, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates new or independent and transparent recommendations and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or information or any of its affiliates to any registration or licensing requirements within such purpose. This Note is not directed or intary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates user severes the redistribution or this document the ecoied from the ecoiyand and person or published,

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited. Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities of thave actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

#### **Disclaimer & Standard warning**

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

#### **Disclosures for U.S. Investors**

The research analyst did not receive compensation from Marico Limited.

Elara Capital Inc.'s affiliate did not manage an offering for Marico Limited

Elara Capital Inc.'s affiliate did not receive compensation from Marico Limited in the last 12 months.

Elara Capital Inc.'s affiliate does not expect to receive compensation from Marico Limited in the next 3 months.

#### **Disclaimer for U.S. Investors**

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in a different currency to the stated date or take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.



#### India

Elara Securities (India) Private Limited One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500

Sales Team

India

#### Europe Elara Capital Plc. 6th Floor, The Grove, 248A Marylebone Road,

London, NW1 6JZ,

Tel: +44 20 7486 9733

United Kingdom

**USA Elara Securities Inc.** 230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870 Fax: +1 212 208 2501 Asia / Pacific Elara Capital (Asia) Pte.Ltd. One Marina Boulevard, Level 20, Singapore 018989 Tel : +65 6978 4047

Managing Director	Harendra Kumar   harendra.kumar@elaracapital.com   +91 22 6164 8571
Head of Research	<b>Dr Bino Pathiparampil</b>   bino.pathiparampil@elaracapital.com   +91 22 6164 8572

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543

Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558

	Lekha Nahar - lekha.nahar@elaracapital.com - +91 22 6164 8512
India, APAC & Australia	<b>Sudhanshu Rajpal</b> - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508 Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541 Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8
India & UK	<b>Prashin Lalvani -</b> prashin.lalvani@elaracapital.com - +91 22 6164 8544
India & US	Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570
e Corporate	

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520 Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

Access our reports on Bloomberg: Type RESP ESEC <GO>

Access,

Conference &

Events

Also available on Thomson & Reuters

8567

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018 Investor Grievance Email ID: <u>investor.grievances@elaracapital.com</u> - Tel. +91 22 6164 8509 Compliance Officer: Mr. Anand Rao - Email ID: <u>anand.rao@elaracapial.com</u> - Tel. +91 22 6164 8509